EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma

Shaji Kumar, Betsy Knopf, Erik Asmus, Morie Gertz, Prashant Kapoor, Suzanne Hayman, Vivek Roy, Amie Fonder, Lisa Christenson, Miriam Hobbs, Leif Bergsagel, Rafael Fonseca und 10 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2026.05.004 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Shaji Kumar und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: kumar.shaji@mayo.edu. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies form the backbone of initial treatment for myeloma and play an important role in the treatment of relapsed disease. However, global access to many novel therapies is limited and alkylating agents remain relevant in certain clinical settings. Ixazomib is an oral PI that enables development of all oral regimens. PATIENTS: We designed this open-label, multi-arm phase 2 study to evaluate the safety and efficacy of weekly oral ixazomib in various combinations for patients with relapsed MM. Herein, we discuss the results of Arms D (ixazomib, cyclophosphamide, and dexamethasone-ICd, n=33) and E (Daratumumab-ICd, n=24) that examined the ixazomib and dexamethasone in combination with cyclophosphamide or cyclophosphamide and daratumumab, respectively. RESULTS: The overall response rate was 73% and 75% and ≥VGPR rate was 45% and 54% in the Arms D and E, respectively. After the median follow-up of 27 months for Arm D and 41 months for Arm E, the median progression free survival was 27.1 months (95% confidence interval [CI]: 17.8-38.6) and 37.7 months (95% CI: 17.9-NA) for the arms D and E, respectively. The median overall survival was not reached for either arm. A grade 3 or higher hematological adverse event considered at least possibly related, occurred in approximately 75% of patients. CONCLUSIONS: The results of this phase 2 trial demonstrate clinically meaningful efficacy of ICd (±) daratumumab in the relapsed setting, with the indirect comparison suggesting a deeper response and longer PFS with adding daratumumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHumansBoron CompoundsCyclophosphamideFemaleAntibodies, MonoclonalDexamethasoneMaleGlycineMiddle AgedAgedAdultAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Alkylating agentIxazomibMonoclonal antibodyProteasome inhibitionRelapsed myelomaSurvival

Substanzen

ixazomibBoron CompoundsCyclophosphamidedaratumumabAntibodies, MonoclonalDexamethasoneGlycine

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: kumar.shaji@mayo.edu.
  • Department of Biostatistics, Mayo Clinic, Rochester, MN.
  • Division of Hematology, Mayo Clinic, Rochester, MN.
  • Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.
  • Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ.

Förderung

  • NCI NIH HHS
  • Mayo Clinic

Zitieren

APA

Kumar, S., Knopf, B., Asmus, E., Gertz, M., Kapoor, P., Hayman, S., Roy, V., Fonder, A., Christenson, L., Hobbs, M., Bergsagel, L., Fonseca, R., Dingli, D., Dispenzieri, A., Gonsalves, W., Kourelis, T., Sher, T., Siddiqi, M., Warsame, R., …, & Buadi, F. (2026). Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.05.004

Vancouver

Kumar S, Knopf B, Asmus E, Gertz M, Kapoor P, Hayman S, et al. Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.05.004

BibTeX
@article{Kumar2026,
  author = {Kumar, Shaji and Knopf, Betsy and Asmus, Erik and Gertz, Morie and Kapoor, Prashant and Hayman, Suzanne and Roy, Vivek and Fonder, Amie and Christenson, Lisa and Hobbs, Miriam and Bergsagel, Leif and Fonseca, Rafael and Dingli, David and Dispenzieri, Angela and Gonsalves, Wilson and Kourelis, Taxiarchis and Sher, Taimur and Siddiqi, Mustaqeem and Warsame, Rahma and Ailawadhi, Sikander and Rajkumar, S Vincent and Buadi, Francis},
  title = {Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.05.004}
}
Kostenlos starten →